AlphaTON’s Cyncado Therapeutics and Australia’s ADDRI to Launch Investigator-Initiated Mesothelioma Clinical Trial of TT-...
Dover, DE and Sydney, Australia, Nov. 12, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (Nasdaq: ATON) and its wholly owned oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics (Cyncado), today announced a non-binding …